Core Viewpoint - Xianju Pharmaceutical is facing a penalty of 195 million yuan due to alleged price monopoly of dexamethasone phosphate sodium raw materials, which includes confiscation of illegal gains and a fine based on sales revenue [2][6]. Group 1: Company Financials - In 2024, Xianju Pharmaceutical reported a revenue of 4 billion yuan, a decrease of 2.98% year-on-year, and a net profit attributable to shareholders of 397 million yuan, down 29.46% year-on-year [6]. - The company has acknowledged the expected liabilities and related losses in its annual report due to the administrative penalty [6]. Group 2: Product Pricing and Market Impact - The price of dexamethasone phosphate sodium injection has seen significant fluctuations, with a reported increase in sales price from 0.63 yuan to 9.8 yuan, marking a 1455.56% increase [2]. - The hanging network prices for Xianju Pharmaceutical's dexamethasone phosphate sodium injection were adjusted multiple times, with recent prices set at 1.87 yuan and 1.03 yuan, reflecting a nearly 91% decrease [4]. - Xianju Pharmaceutical's dexamethasone phosphate sodium injection was not selected in the national centralized procurement, with the lowest winning price being 2.3 yuan per box [5]. Group 3: Regulatory and Market Context - The company is under scrutiny for its pricing practices, as evidenced by a previous case involving another company that faced penalties for price gouging of the same drug [2]. - The national drug procurement policy has significantly impacted the sales revenue of Xianju Pharmaceutical's products, particularly for common drugs like dexamethasone phosphate sodium injection [6].